
|Videos|December 27, 2022
Scynexis CEO talks recent ibrexafungerp approval
Author(s)Morgan Ebert, Managing Editor
Marco Taglietti, MD, president and CEO of Scynexis, sits with Contemporary OB/GYN® to discuss the recent approval of ibrexafungerp (Brexafemme) for the reduction in incidence of recurrent vulvovaginal candidiasis.
Advertisement
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
FDA approves Aptima HPV assay for clinician-collected primary cervical cancer screening
2
Kevin Ault, MD, on maternal immunization, following the correct recommendations
3
Fionnuala McAuliffe, MD, highlights importance of timely breastfeeding discussions with patients
4
ACOG calls for safe, equitable ob-gyn care for immigrants
5









